SillaJen Inc (215600 KS): Baselia Deal Enriches Pipeline; Stock Trading Resumption Decision Soon
Despite recent acquisition of a first-in-class oncology drug candidate, SillaJen is a risky bet amid regulatory crackdown and past clinical trial...
383 Views
Basilea Pharmaceutica - Strategic streamlining – sale of oncology assets
Management continues to execute its strategic plan and has announced the sale of its novel poly (ADP-ribose) glycohydrolase (PARG) inhibitor...
662 Views
Basilea Pharmaceutica - To retire converts with senior secured and cash
Despite the challenging financial backdrop, Basilea Pharmaceutica has announced that it has secured a CHF75m senior secured loan from Athyrium...
652 Views
Basilea Pharmaceutica - On track for operating profitability in FY23
Basilea’s H122 revenues of CHF58.7m were roughly in-line with our annualised estimates (FY22e: CHF110m) and company guidance, including CHF28.9m in...
676 Views
Basilea Pharmaceutica - Zevtera path to US approval open
On 28 June 2022, Basilea announced positive top-line results from the Phase III ERADICATE study, investigating the use of its drug-resistant...
665 Views